|
Market Closed -
Australian S.E.
08:12:42 09/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 183.84 AUD | +1.31% |
|
+4.84% | +6.48% |
| 10-09 | CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform | MT |
| 10-08 | Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027 | DJ |
Company Valuation: CSL Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 89,299 | 89,052 | 95,184 | 76,024 | 38,015 | 61,440 | - | - |
| Change | - | -0.28% | 6.89% | -20.13% | -50% | 61.62% | - | - |
| Enterprise Value (EV) 1 | 88,520 | 99,731 | 105,710 | 85,005 | 47,398 | 70,672 | 70,359 | 69,843 |
| Change | - | 12.66% | 5.99% | -19.59% | -44.24% | 49.1% | -0.44% | -0.73% |
| P/E | 38.6x | 40.8x | 36.1x | 25.4x | -14.8x | 21.2x | 19.2x | 18.2x |
| PBR | 6.13x | 5.64x | 5.48x | 3.93x | 2.57x | 3.78x | 3.46x | 3.15x |
| PEG | - | -7.25x | 1.8x | 1.9x | 0x | -0x | 1.9x | 3.4x |
| Capitalization / Revenue | 8.45x | 6.69x | 6.43x | 4.89x | 2.41x | 3.9x | 3.77x | 3.61x |
| EV / Revenue | 8.38x | 7.49x | 7.14x | 5.46x | 3x | 4.49x | 4.31x | 4.1x |
| EV / EBITDA | 24.6x | 25.6x | 22.3x | 16.5x | 10.7x | 13.9x | 13.2x | 12.5x |
| EV / EBIT | 30.2x | 32.5x | 27.7x | 19x | 10.3x | 16.2x | 15.3x | 14.5x |
| EV / FCF | 57.1x | 72.6x | 55.2x | 29.1x | 16.5x | 22.5x | 24x | 22.6x |
| FCF Yield | 1.75% | 1.38% | 1.81% | 3.44% | 6.05% | 4.45% | 4.17% | 4.42% |
| Dividend per Share 2 | 2.22 | 2.36 | 2.64 | 2.92 | 2.92 | 2.996 | 3.178 | 3.412 |
| Rate of return | 1.2% | 1.28% | 1.34% | 1.86% | 3.68% | 2.34% | 2.48% | 2.66% |
| EPS 2 | 4.8 | 4.53 | 5.45 | 6.17 | -5.35 | 6.063 | 6.68 | 7.038 |
| Distribution rate | 46.3% | 52.1% | 48.4% | 47.3% | -54.6% | 49.4% | 47.6% | 48.5% |
| Net sales 1 | 10,562 | 13,310 | 14,800 | 15,558 | 15,797 | 15,757 | 16,316 | 17,015 |
| EBITDA 1 | 3,596 | 3,900 | 4,750 | 5,151 | 4,438 | 5,081 | 5,320 | 5,597 |
| EBIT 1 | 2,927 | 3,069 | 3,812 | 4,468 | 4,620 | 4,364 | 4,587 | 4,824 |
| Net income 1 | 2,255 | 2,194 | 2,642 | 3,002 | -2,579 | 2,822 | 3,149 | 3,348 |
| Net Debt 1 | -778.6 | 10,679 | 10,526 | 8,981 | 9,383 | 9,232 | 8,919 | 8,403 |
| Reference price 2 | 185.38 | 184.61 | 196.96 | 157.01 | 79.38 | 128.29 | 128.29 | 128.29 |
| Nbr of stocks (in thousands) | 481,706 | 482,372 | 483,253 | 484,212 | 478,912 | 478,912 | - | - |
| Announcement Date | 8/16/22 A | 8/14/23 A | 8/12/24 A | 8/18/25 A | 8/17/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.16x | 4.49x | 13.91x | 2.34% | 61.44B | |
| 33.55x | 12.18x | 25.21x | 0.58% | 1,051B | |
| 29.08x | 6.43x | 18.37x | 2.04% | 630B | |
| 35.19x | 8.13x | 16.76x | 2.51% | 489B | |
| 105.8x | 5.93x | 25.27x | 2.34% | 359B | |
| 19.31x | 4.72x | 11.72x | 2.8% | 344B | |
| 20.06x | 5.27x | 12.98x | 3.02% | 272B | |
| 20.57x | 4.22x | 12.06x | 2.1% | 246B | |
| 26.34x | 6.83x | 12.21x | 2.43% | 224B | |
| -45.84x | 6.75x | 26.31x | 2.18% | 187B | |
| Average | 26.52x | 6.49x | 17.48x | 2.23% | 386.51B | |
| Weighted average by Cap. | 32.23x | 7.79x | 19.25x | 1.91% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CSL Stock
- Valuation CSL Limited
Select your edition
All financial news and data tailored to specific country editions
